Announcing New Initiatives, RFK Jr Continues Push for Americans to Discontinue Antidepressants

On Monday, May 4, 2026, US Department of Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr announced several initiatives to rein in the prescription of selective serotonin reuptake inhibitors (SSRIs), the most widely prescribed class of antidepressants. These announcements and initiatives have intensified discussion surrounding the use of SSRIs, their discontinuation, and broader approaches to mental health care.¹

SSRIs are used to treat depression and anxiety in the US. In 2025, approximately 16.6% of US adults reported taking an SSRI, underscoring the widespread reliance on this medication class. Their popularity has historically been attributed to favorable tolerability compared with older antidepressants and accessibility through primary care prescribing.¹

Although these drugs are not considered controlled substances, stopping them abruptly can lead to antidepressant discontinuation syndrome, a transient cluster of symptoms (eg, dizziness, insomnia, flu-like symptoms) that typically resolves with dose tapering. In comparison, addiction may mean requiring more of the drug to feel an effect or uncontrollable use. Some health care professionals worry that public misperceptions fueled by political statements could worsen stigma surrounding psychiatric medications and mental illness.²

As reported by The New York Times, Kennedy said, “Psychiatric medications have a role in care, but we will no longer treat them as the default; we will treat them as one option, to be used when appropriate, with full transparency and with a clear path off when they are no longer needed.”

What Are These New Initiatives?

Recent policy announcements from HHS aim to recalibrate how these medications are used in clinical practice. Proposed initiatives include new clinician training programs, updated reimbursement mechanisms, and the development of clinical guidelines focused on deprescribing psychiatric medications. The Centers for Medicare & Medicaid Services plans to introduce reimbursement pathways for clinicians who spend time supporting patients during medication tapering, while the Substance Abuse and Mental Health Services Administration is expected to release training modules on deprescribing and risk communication.¹

Collectively, these efforts appear to emphasize a shift toward shared decision-making, informed consent, and greater integration of nonpharmacologic interventions such as psychotherapy, exercise, and nutrition.¹

What Do Pharmacists Need to Know?

Despite these policy directions, professional organizations have urged caution regarding broad claims of SSRI overprescribing. Experts note that both overuse and underuse of psychiatric medications exist, and access to mental health care remains a significant barrier for many patients.¹ As such, individualized care continues to be a central principle in psychiatric treatment.

Evidence on the prevalence and severity of discontinuation symptoms remains mixed. Some studies suggest that a substantial proportion of patients experience withdrawal effects, whereas others indicate that severe symptoms occur in a relatively small minority.¹ This variability reinforces the importance of individualized tapering strategies and patient education.

Pharmacists are uniquely positioned to address these challenges. As highly accessible health care professionals, they play a central role in counseling patients on the safe use and discontinuation of SSRIs. Pharmacists can clarify the difference between withdrawal and addiction, provide guidance on expected symptoms, and emphasize the importance of gradual tapering to minimize adverse effects (AEs). Additionally, they can develop personalized tapering schedules, assess for drug interactions, and monitor for complications such as serotonin syndrome when SSRIs are used alongside other serotonergic agents.²

Collaborative practice agreements further expand the pharmacist’s role, enabling participation in dose adjustments and deprescribing efforts under physician supervision. In community settings, pharmacists may identify patients attempting to discontinue medications independently and intervene to prevent relapse or complications.² These contributions are essential to maintaining treatment adherence and optimizing outcomes in psychiatric care.

Nonpharmaceutical Intervention Methods

Beyond pharmacotherapy, emerging discussions also highlight the role of lifestyle interventions in mental health. Alongside the US Department of Agriculture, Kennedy has encouraged US citizens to “eat real food,” and promoted dietary changes such as an increased protein intake (1.2-1.6 g/kg of body weight per day) while cutting ultraprocessed foods and sugars.^3,4

Another one of these recommendations suggests the ketogenic (keto) diet as a potential tool in managing psychiatric conditions.³ Although preliminary research suggests that the keto diet may improve metabolic and psychiatric outcomes in certain populations, current evidence remains limited and should be interpreted cautiously. Importantly, such interventions are not substitutes for established pharmacologic treatments; however, they may serve as adjunctive strategies when done effectively and with clinical supervision.³

Pharmacists again play a critical role in this domain by helping patients navigate dietary changes safely. The ketogenic diet can significantly impact glucose levels, electrolyte balance, and medication efficacy, particularly in patients with comorbid conditions. Pharmacists can identify risks, monitor for AEs, and provide guidance on nutrient supplementation and medication adjustments.³ Their involvement helps ensure that lifestyle interventions are implemented safely and effectively.

Understanding Policy Changes and Their Impact on Mental Health Services

Policy changes at the federal level may also influence access to mental health services. Proposed restructuring within HHS and potential funding shifts could affect programs supporting psychiatric care, particularly in underserved settings. In this context, pharmacists working in community pharmacies, federally qualified health centers, and integrated care models may play an increasingly important role in bridging gaps in access. Services such as medication therapy management, screening, and telehealth coordination could help sustain continuity of care as the health system evolves.²

Federal initiatives and public discourse have brought renewed attention to the use and discontinuation of SSRIs, as well as broader mental health treatment strategies.^1-3 Although policy efforts state they aim to enhance patient autonomy and expand treatment options, maintaining evidence-based care and clear communication remains essential. Pharmacists are central to this effort, serving as trusted sources of information, ensuring safe medication use, and supporting patients through pharmacologic and nonpharmacologic approaches to mental health care.^2,3

“Let me be clear: If you are taking psychiatric medication, we are not telling you to stop. We are making sure you—and your clinician—have the information and support to make the right decision for you,” Kennedy stated. “Our goal is straightforward: to reduce unnecessary dependence on medication, to improve patient outcomes, and to return control to the patients.”¹

REFERENCES

1. Barry E. Kennedy starts a push to help Americans quit antidepressants. New York Times. May 4, 2026. Accessed May 6, 2026. https://www.nytimes.com/2026/05/04/science/rfk-antidepressants-ssris-hhs-maha.html?smid=nytcore-ios-share

2. Valletti D. HHS secretary's SSRI remarks renew focus on pharmacists’ role in mental health care. Pharmacy Times. October 10, 2025. Accessed May 6, 2026. https://www.pharmacytimes.com/view/hhs-secretary-s-ssri-remarks-renew-focus-on-pharmacists-role-in-mental-health-care

3. McGovern G. Can the Keto Diet “cure” schizophrenia? Pharmacy Times. February 9, 2026. Accessed May 6, 2026. https://www.pharmacytimes.com/view/can-the-keto-diet-cure-schizophrenia-

4. Valletti D. New federal dietary guidelines emphasize protein and real foods while cutting sugar. Pharmacy Times. January 8, 2026. Accessed May 6, 2026. https://www.pharmacytimes.com/view/new-federal-dietary-guidelines-emphasize-protein-and-real-foods-while-cutting-sugar